Global Nicotine Replacement Therapy Market is valued approximately USD 38 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 16.3 % over the forecast period 2020-2027. Nicotine replacement therapy (NRT) is recommended for tobacco cessation. As tobacco smoking contains nicotine, which is addictive and harmful for health , as it causes lung cancer and other respiratory and cardiac diseases. Nicotine replacement therapy (NRT) includes all the products, drugs, counselling as well as psychotherapy. The rising government strict norms towards the use of tobacco and increasing awareness regarding the negative impact of smoking on health are the few factors responsible for growth of the market over the forecast period. For instance: as per Centre of Public Impact Organization, in February 2010, the Dutch Supreme Court issued an amendment in Tobacco Act, banned the smoking in owner-run pubs and cafs without employees, thus rejecting an earlier ruling where small bar and caf owners were exempt. Also, as per Statista, the number of tobacco smokers among those aged 15 years and older in Europe was 209 million people in 2015 and has decreased to 195 million people in 2020. The number of tobacco smokers among those aged 15 years and older in America was 132 million people in 2015 and has decreased to 121 million people in 2020. This decrease in number of smoking leads to huge adoption of Nicotine Replacement Therapy across the world. However, the certain side effects from Nicotine replacement therapy (NRT) products and drugs is the major factor restraining the growth of global Nicotine Replacement Therapy market during the forecast period.


The regional analysis of global Nicotine Replacement Therapy market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising awareness against smoking hazards and high accessibility of nicotine replacement therapy products. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:
Philip Morris Products S.A. (Altria Group)
British American Tobacco p.l.c.
Japan Tobacco, Inc.
Imperial Brands
Glenmark
Fertin Pharma
Cipla Inc.
Pfizer Inc.
Johnson & Johnson Services, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Nicotine Replacement Therapy
E-cigarettes
Heat-not-burn Tobacco Products

By Distribution Channel:
Offline
Online

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018
Base year 2019
Forecast period 2020 to 2027

Target Audience of the Global Nicotine Replacement Therapy Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors